Mouth spray – ColdZyme to deactivate SARS-CoV-2
Swedish life science company – Enzymatica that develops and sells health care products for primary conditions of the ear-nose-and-throat region revealed that the preliminary results of an in vitro study showed that the mouth spray ColdZyme® can deactivate SARS-CoV-2 – coronavirus. The research showed that ColdZyme deactivates SARS-CoV-2 coronavirus by 98.3% (1.76 log\10\). The outcomes of the study suggest that by local virus deactivation in the mouth ColdZyme can offer a protective barrier against harmful viruses such as SARS-CoV-2.
A barrier is formed against common cold viruses in the oral cavity by the ColdZyme mouth spray. The barrier solution of the mouth spray is composed of Atlantic cod trypsin and glycerol. Determining the ability of ColdZyme to deactivate the coronavirus that causes COVID-19 was the aim of the current study. Using ColdZyme, a virucidal efficacy suspension test was carried out against SARS-CoV-2 coronavirus. In just 20 minutes, ColdZyme deactivated 98.3% (1.76 log10) of SARS-CoV-2. Additionally, ColdZyme did not show any cytotoxicity at any dilution examined. The US firm Microbac Laboratories Inc had conducted the research work.
The in vitro research study was based upon a standardized as well as validated methodology, i.e. ASTM International test method designated E1052 ‘Standard Test Method to Assess the Activity of Microbicides against Viruses in Suspension’.
The earlier studies in vitro using the same method showed that ColdZyme works against another coronavirus, which causes the common cold – HCoV-229E as well, and in contrast to SARS-CoV-2 that causes COVID-19 belongs to another subgroup within the family – Corona. All the results gathered show that ColdZyme can be effective against a range of coronaviruses.
The coronavirus – SARS-CoV-2 proactively reproduces in the throat and shows high viral shedding even while only moderate symptoms are shown up. As a result, ColdZyme sprayed onto the mouth and throat could lower the risk of infection, and reduce the viral load in your mouth and oral community. The reduced viral load may lower viral shedding and hence minimize the spread of COVID-19.
Claus Egstrand, Enzymatica’s chief operating officer said that even if the present in vitro results can not be directly translated right into clinical efficiency, it is really interesting that ColdZyme has the ability to effectively deactivate coronavirus in vitro since it constitutes a proof-of-principle that can be taken further into clinical research. Therefore, the outcomes of the study show that ColdZyme can offer a protective barrier against COVID-19.
Author: Sruthi S